Sign in
Taking peopleNo phase

Biomarkers for Ventilator-associated Pneumonia

Key facts

Who runs it
Region Skane
Where
Norway, Portugal, and Sweden5 sites in 3 countriesChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
1,000 people, planned
Started
15 Oct 2021
Expected to end
31 Dec 2028
Type of study
Observational, 3 groups
Treatments tested
  • Heparin-binding protein
  • Interleukin-26
  • Microbiome
  • Bacterial transcriptome
  • Proteome
Record updated
26 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Admission to an intensive care unit
  • Intubation within last 24 hours
  • Anticipated mechanical ventilation of at least 48 hours

Who cannot take part

  • Ongoing infection of the lungs at admission to the ICU
  • Severe coagulopathy (spontaneous PK(INR) >1.8 or thrombocytes <50). Prophylaxis treatment dose of LMWH or factor Xa inhibitors/NOAC is not an exclusion criteria. If higher doses of these substances are administered, the responsible clinician should be consulted before sample collection
  • FiO2 above 70% or PEEP above 15
  • Severely elevated or instable intracranial pressure

This trial has no sites in United States.

It has sites in 3 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate different peptide biomarkers, variations in the microbiome and patterns in the bacterial transcriptome as prognostic or diagnostic biomarkers of VAP.

The 3 groups in the trial

  • VAP

    Enrolled participants that fully meet the criteria of VAP.

    Treatment: Heparin-binding protein, Interleukin-26, Microbiome, Bacterial transcriptome, and Proteome

  • Suspect VAP

    Enrolled participants that develop signs of VAP but lack some variable, for instace new radiographic infiltrate or microbiological finding compatible with VAP.

    Treatment: Heparin-binding protein, Interleukin-26, Microbiome, and Proteome

  • No VAP

    Enrolled participants that do not develop VAP.

    Treatment: Heparin-binding protein, Interleukin-26, Microbiome, and Proteome

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Biomarkers for Prediction of and Diagnosis of Ventilator-associated Pneumonia
Record updated
26 June 2026